TNDM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tandem Diabetes Care Inc (TNDM) is not a strong buy at this moment for a beginner, long-term investor. Despite recent analyst upgrades and potential growth from the pharmacy model transition, the company's financial performance shows declining net income and EPS, and technical indicators suggest a neutral to slightly bearish short-term trend. Given the lack of strong proprietary trading signals and no immediate positive news catalysts, it is better to hold off on buying for now.
The technical indicators are mixed. The MACD is slightly positive but contracting, RSI is neutral at 43.143, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading below the pivot level (23.693), with support levels at 21.603 and 20.313. Short-term stock trend analysis indicates a 70% chance of a -2.95% decline in the next week and -6.77% in the next month.
Analysts have recently upgraded the stock with higher price targets, citing growth potential from the pharmacy model transition and new product launches.
Hedge funds are significantly increasing their positions, with an 870.81% increase in buying activity last quarter.
Financial performance in Q4 2025 shows a significant decline in net income (-178.01% YoY) and EPS (-200.00% YoY), despite a slight revenue increase.
No recent news or event-driven catalysts to support immediate stock momentum.
Short-term stock trend analysis predicts a decline over the next week and month.
In Q4 2025, revenue increased by 2.74% YoY to $290.38M, and gross margin improved to 57.67% (up 3.52% YoY). However, net income dropped significantly to -$589K (-178.01% YoY), and EPS fell to -$0.01 (-200.00% YoY), indicating profitability challenges.
Analysts are optimistic about the stock's long-term potential, with multiple upgrades and increased price targets. Recent upgrades include Truist (Buy, PT $35), Piper Sandler (Overweight, PT $33), and Lake Street (Buy, PT $50). Analysts highlight the transition to a pharmacy model, new product launches, and potential for recurring revenue growth as key drivers. However, some firms remain cautious, maintaining Neutral ratings due to near-term uncertainties.
